Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s423, 2024. DOI: 10.25251/skin.8.supp.423. Disponível em: https://skin.dermsquared.com/skin/article/view/3090. Acesso em: 19 may. 2025.